Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts assign Assembly Biosciences a consensus recommendation of "Moderate Buy" from seven brokers (five buys, one hold, one sell) with an average 1‑year price target of $42.75, and recent notable calls include HC Wainwright's $50 buy and Guggenheim raising its target to $43.
• In the most recent quarter Assembly reported a surprising $2.48 EPS (vs. consensus -$0.51) and revenue of $42.47M (vs. $7.42M est.), though the company still posts a negative net margin and negative return on equity.
• Shares trade near $31.36 with a market capitalization of about $498.4M, a 52‑week range of $11.64–$39.71, and roughly 19.9% ownership by hedge funds and other institutions.

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $42.75.

Several research analysts recently issued reports on ASMB shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Assembly Biosciences in a research report on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Assembly Biosciences in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Assembly Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Sunday, March 29th. Finally, Guggenheim upped their price target on shares of Assembly Biosciences from $39.00 to $43.00 and gave the company a "buy" rating in a research report on Monday, April 6th.

Institutional Trading of Assembly Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 3,319 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $147,000. Charles Schwab Investment Management Inc. purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $228,000. Virtus Investment Advisers LLC purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $251,000. Finally, Engineers Gate Manager LP purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $353,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Stock Performance

Shares of NASDAQ:ASMB opened at $31.36 on Thursday. Assembly Biosciences has a 52-week low of $11.64 and a 52-week high of $39.71. The firm has a fifty day moving average of $28.64 and a 200 day moving average of $30.54. The firm has a market capitalization of $498.40 million, a PE ratio of -42.38 and a beta of 1.08.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million. On average, sell-side analysts forecast that Assembly Biosciences will post -0.93 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.